Title
Do margins matter? the influence of positive surgical margins on prostate cancer-specific mortality
Date Issued
01 April 2014
Access level
metadata only access
Resource Type
journal article
Author(s)
Stephenson A.
Eggener S.
Klein E.
Kattan M.
Wood D.
Rabah D.
Eastham J.
Scardino P.
Fundación Clínica Cleveland
Publisher(s)
Elsevier B.V.
Abstract
Background Positive surgical margins (PSMs) in radical prostatectomy (RP) specimens are a frequent indication for adjuvant radiotherapy and are used as a measure of surgical quality. However, the association between PSMs and prostate cancer-specific mortality (CSM) is poorly defined. Objective Analyze the association of PSMs with CSM, adjusting for fixed and time-dependent parameters. Design, setting, and participants Fine and Gray competing risk regression analysis was used to model the clinical data and follow-up information of 11 521 patients treated by RP between 1987 and 2005. Two extended models were used that adjusted for the use of postoperative radiotherapy, which was handled as a time-dependent covariate. Postoperative radiotherapy was modeled as a single parameter and also as early and late therapy, based on the prostate-specific antigen level at the start of treatment (≤0.5 vs >0.5 ng/ml). Intervention RP for clinically localized prostate cancer and selective use of secondary local and/or systemic therapy. Outcome measurements and statistical analysis The outcome measure was prostate cancer-specific mortality. Results and limitations The 15-yr CSM rates for patients with PSMs and negative surgical margins were 10% and 6%, respectively (p < 0.001). No significant association between PSM and CSM was observed in the conventional model with fixed covariates (hazard ratio [HR]: 1.04; 95% confidence interval [CI], 0.7-1.5; p = 0.8) or in the two extended models that adjusted for postoperative radiotherapy (HR: 0.96; 95% CI, 0.7-1.4; p = 0.9), or early and late postoperative radiotherapy (HR: 1.01; 95% CI, 0.7-1.4; p = 0.9). Conclusions PSMs alone are not associated with a significantly increased risk of CSM within 15 yr of RP. However, urologists should continue to strive to avoid PSMs, as they increase a man's risk of biochemical recurrence and need for secondary therapy and may be a source of considerable patient anxiety. © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Start page
675
End page
680
Volume
65
Issue
4
Language
English
OCDE Knowledge area
Urología, Nefrología
Subjects
Scopus EID
2-s2.0-84894497044
PubMed ID
Source
European Urology
ISSN of the container
03022838
Source funding
Robert Wood Johnson Foundation
Sponsor(s)
Funding/Support and role of the sponsor: Andrew J. Stephenson was supported in part by a grant under the Robert Wood Johnson Foundation Physician Faculty Scholars Program and the Astellas/American Urological Association Rising Stars in Urology Program.
Sources of information:
Directorio de Producción Científica
Scopus